LCE1D Inhibitors
LCE1D Inhibitors encompass an array of chemical compounds that influence the differentiation and proliferation of keratinocytes, subsequently impacting the expression and function of LCE1D in the skin's epidermal barrier. Retinoic acid and tazarotene, being derivatives of vitamin A and its analogues, function by enhancing keratinocyte differentiation, thereby potentially diminishing the LCE1D protein's role in the later stages of epidermal formation. Similarly, calcipotriol mimics vitamin DLCE1D Inhibitors encompass a diverse set of chemical compounds that indirectly reduce the functional activity of LCE1D through mechanisms impacting keratinocyte behavior. Retinoic acid and tazarotene, both related to vitamin A signaling, promote keratinocyte differentiation, which may lessen the demand for LCE1D's involvement in late differentiation and barrier formation. Similarly, calcipotriol, a vitamin D3 analogue, could decrease LCE1D expression by favoring differentiation over proliferation. Anthralin and methotrexate, with their respective roles in slowing keratinocyte proliferation, could suppress LCE1D function by lessening the cellular demand for its barrier-forming capabilities. Imiquimod's immunomodulatory effects can induce keratinocyte remodeling, a process where LCE1D's contribution might be deemed less critical, leading to its functional inhibition.
Other inhibitors act through immunological or cytotoxic pathways to modulate keratinocyte turnover and viability, which indirectly impacts LCE1D expression or necessity. Cyclosporin A and FK-506, as immunosuppressants, affect T-cell activation and can alter keratinocyte dynamics, potentially diminishing LCE1D's role in maintaining barrier integrity. Hydroquinone and benzoyl peroxide, by influencing keratinocyte viability and turnover, might lead to a reduced requirement for LCE1D in the skin barrier. Salicylic acid, as a keratolytic, facilitates the shedding of keratinocytes, and coal tar addresses keratinocyte proliferation and differentiation, each potentially reducing the functional need for LCE1D in forming a resilient epidermal barrier. Collectively, these LCE1D inhibitors, though not directly targeting the protein, exert their effects through biochemical pathways that result in a diminished role for LCE1D in the skin's structural defense.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid, a metabolite of vitamin A, can regulate keratinocyte differentiation and proliferation. As LCE1D is involved in epidermal barrier function and is expressed in differentiated keratinocytes, retinoic acid could lead to the functional inhibition of LCE1D by promoting differentiation, thus reducing the need for LCE1D's role in barrier formation. | ||||||
Calcipotriol | 112965-21-6 | sc-203537 sc-203537A | 10 mg 50 mg | $203.00 $832.00 | 4 | |
Calcipotriol is a synthetic vitamin D3 analogue that modulates keratinocyte proliferation and differentiation. It could diminish LCE1D function by enhancing the differentiation of keratinocytes, thereby indirectly inhibiting LCE1D expression, which is associated with late differentiation. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
Imiquimod, an immune response modifier, can trigger local inflammation and alter keratinocyte activity. It may indirectly inhibit LCE1D by activating immune pathways that lead to keratinocyte apoptosis or remodeling, processes that may not require LCE1D's barrier function. | ||||||
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
Tazarotene is a topical retinoid that modulates keratinocyte differentiation. By promoting the differentiation of keratinocytes, tazarotene could indirectly inhibit LCE1D expression, as LCE1D is primarily involved in the late differentiation stages necessary for the epidermal barrier. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A can affect keratinocyte growth and differentiation. It may lead to diminished LCE1D function through immunomodulatory effects that impact keratinocyte turnover and reduce the demand for LCE1D's role in barrier formation. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate, an antimetabolite, can interfere with cell proliferation, including keratinocytes. It could indirectly inhibit LCE1D by decreasing keratinocyte proliferation, thus reducing the expression of LCE1D, which is associated with epidermal differentiation and barrier function. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $78.00 $151.00 | 9 | |
FK-506 affects T-cell activation and can also influence keratinocyte behavior. It may lead to a decrease in LCE1D's functional role by modulating immune responses and keratinocyte differentiation, thereby affecting skin barrier integrity. | ||||||
Hydroquinone | 123-31-9 | sc-204773 sc-204773A sc-204773B | 250 g 1 kg 5 kg | $37.00 $93.00 $400.00 | ||
Hydroquinone is a skin lightening agent that can cause cytotoxicity in melanocytes and potentially affect keratinocytes. It might diminish LCE1D function by altering keratinocyte viability and proliferation, which are processes that LCE1D is involved in. | ||||||
Salicylic acid | 69-72-7 | sc-203374 sc-203374A sc-203374B | 100 g 500 g 1 kg | $47.00 $94.00 $119.00 | 3 | |
Salicylic acid, a keratolytic agent, can facilitate the shedding of keratinocytes. This might lead to the inhibition of LCE1D by reducing the build-up of keratinocytes that require LCE1D for proper barrier formation and function. | ||||||